Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | MITF | O75030 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | SLC5A2 | P31639 | 6/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4633222 | 0.83 | MEN1 (0.41) | KMT2AMEN1L3MBTL1SLC5A2 | |
| SCHEMBL12530571 | 0.83 | MEN1 (0.51) | KMT2AMEN1L3MBTL1ALDH1A1MAPT | |
| SCHEMBL12530942 | 0.82 | L3MBTL1 (0.47) | KMT2AMEN1L3MBTL1ALDH1A1MAPT | |
| SCHEMBL14903569 | 0.82 | L3MBTL1 (0.47) | KMT2AMEN1L3MBTL1ALDH1A1MAPT | |
| SCHEMBL1294026 | 0.80 | KMT2A (0.53) | KMT2AMEN1L3MBTL1ALDH1A1MAPT | |
| SCHEMBL16579690 | 0.80 | MEN1 (0.38) | KMT2AMEN1L3MBTL1SLC5A2 | |
| SCHEMBL7155506 | 0.78 | KMT2A (0.57) | KMT2AMEN1L3MBTL1ALDH1A1MAPT | |
| SCHEMBL22762718 | 0.78 | KMT2A (0.56) | KMT2AMEN1L3MBTL1ALDH1A1MAPT | |
| SCHEMBL9299015 | 0.76 | KMT2A (0.54) | KMT2AMEN1L3MBTL1ALDH1A1MAPT | |
| SCHEMBL18091411 | 0.76 | KMT2A (0.54) | KMT2AMEN1L3MBTL1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130109735-A1 | SALACINOL AND PONKORANOL HOMOLOGUES, DERIVATIVES THEREOF, AND METHODS OF SYNTHESIZING SAME | SIMON FRASER UNIVERSITY (CA) | 2013-05-02 | — | — | US | disclosed |
| US-20130109735-A1 | SALACINOL AND PONKORANOL HOMOLOGUES, DERIVATIVES THEREOF, AND METHODS OF SYNTHESIZING SAME | SIMON FRASER UNIVERSITY (CA) | 2013-05-02 | — | — | US | disclosed |
| US-20130109735-A1 | SALACINOL AND PONKORANOL HOMOLOGUES, DERIVATIVES THEREOF, AND METHODS OF SYNTHESIZING SAME | SIMON FRASER UNIVERSITY (CA) | 2013-05-02 | — | — | US | disclosed |
| WO-2011066653-A1 | SALACINOL AND PONKORANOL HOMOLOGUES, DERIVATIVES THEREOF, AND METHODS OF SYNTHESIZING SAME | SIMON FRASER UNIVERSITY (CA) | 2011-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109735-A1 | SALACINOL AND PONKORANOL HOMOLOGUES, DERIVATIVES THEREOF, AND METHODS OF SYNTHESIZING SAME | GBA3, SI, GANAB | KMT2A 3965/4885MEN1 4823/4885L3MBTL1 1230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.